Biography for Damian Garde
Damian Garde, Editor
Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at email@example.com and follow @DamianFierce on Twitter.
Articles by Damian Garde
Enzo Biochem picked up a $7 million settlement in its ongoing patent squabble with PerkinElmer, resolving one of its many legal wrangles in life sciences.
Germany's Definiens has raised €15 million ($20.4 million) in new financing to expand into digital tissue diagnostics, planning to use Big Data and image analysis to spot cancers.
Navidea Biopharmaceuticals secured the FDA's blessing to market Lymphoseek, its diagnostic aid, for use in head and neck cancer patients.
Paris' Enterome Biosciences has signed a deal with the Mayo Clinic to collaborate on tests that look to the microbiome to predict patient response to obesity treatment.
After finding success using its technology to screen unborn babies for chromosomal problems, Natera is looking to see how well its diagnostic platform can detect and monitor cancer.
Sequenom, a contender in the crowded field of noninvasive prenatal testing, has recruited global giant Quest Diagnostics to expand the market for the company's MaterniT21 Plus system.
Austin, TX's Apollo Endosurgery traded $90 million for Allergan's under-performing Lap-Band technology last year, and now the company is rolling out a marketing effort of its own, looking to succeed where its forebear struggled.
Despite shifting reimbursement policies and industrywide pricing pressures, it's a good time to be a medical device sales rep, according to a new survey. The sector's sellers are making more money than their pharma counterparts, MedReps.com reports, and they picked up a 5% raise over last year.
Singapore medical device outfit Biosensors International is shaking up its boardroom after a tepid financial performance, working to move on from what it deemed "a challenging year."
Belgian-Israeli startup Nyxoah picked up €8 million ($10.9 million) in financing to advance its tiny neurostimulation treatment for obstructive sleep apnea.